Promising Three-Drug cocktail targets tough leukemia mutation

NCT ID NCT06611839

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs—venetoclax, ivosidenib, and azacitidine—in adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML). The goal is to see if this triple therapy can improve remission rates and survival compared to standard treatments. The trial enrolls 23 participants and includes induction, consolidation, and maintenance phases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax, ivosidenib, and azacitidine
What this could lead to: If successful, this triple-drug combination could become a new standard treatment for IDH1-mutated AML, offering higher remission rates and longer survival.
What could go wrong: This is an early-phase trial with only 23 participants, so results may not apply to all patients. Side effects from the drugs could be serious, and the regimen may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML IDH1 MUTATION TREATMENT

Contacts and locations

Locations

Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.